Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Prurigo Nodularis Clinical Trials
Prurigo Nodularis clinical trials are recruiting across 177 cities. Here are the cities with the most active studies:
Prurigo Nodularis Trial Phases
70 research organizations are sponsoring prurigo nodularis trials.
About Prurigo Nodularis
Prurigo nodularis is a chronic skin condition characterized by intensely itchy, hard lumps on the skin that develop from repeated scratching. It significantly impacts quality of life and sleep. Treatment includes topical therapies, phototherapy, and newer targeted biologics.
Clinical trials are advancing new treatments for prurigo nodularis. Currently, 100 studies are recruiting a combined 73,215 participants across the United States. Research is being conducted by 70 organizations including UMC Utrecht, Pfizer, University of Manitoba and 67 others.
2026 Prurigo Nodularis Research Landscape
As of September 2026, the prurigo nodularis clinical trial landscape includes 100 actively recruiting studies across 177 cities in the United States. These studies are collectively seeking 73,215 participants, with an average enrollment target of 732 per study.
The research spans multiple phases of development: 34 studies are in NA, 22 studies are in PHASE2, 12 studies are in PHASE3, 9 studies are in PHASE1, 9 studies are in PHASE4. The presence of Phase 3 trials indicates that some prurigo nodularis treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 70 different organizations, including UMC Utrecht, Pfizer, University of Manitoba, University of Utah, Sanofi, and 65 others. The large number of sponsors reflects significant research interest and investment in prurigo nodularis treatment advancement.
Geographically, prurigo nodularis trials are most concentrated in Philadelphia, Pennsylvania (10 trials); Chicago, Illinois (9 trials); New York, New York (8 trials); Cincinnati, Ohio (8 trials); Rochester, Minnesota (8 trials) and 7 other cities.
Featured Prurigo Nodularis Studies
Highlighted recruiting studies for prurigo nodularis, selected by enrollment size and research scope.
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in ...
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
The purpose of this study is to learn about how well the 20-valent pneumococcal conjugate vaccine (20vPnC) works against radiologically-confirmed community-acquired pneumonia (RAD+CAP) due to the 7 new serotypes (types of a bacteria called Streptococcus pneumoniae that cause pneumonia) included in 20vPnC vaccine. This study is seeking participants who: * are male or female ≥65 years of age. * ar...
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).
Frequently Asked Questions About Prurigo Nodularis Clinical Trials
Are there prurigo nodularis clinical trials near me?
Yes, there are 100 prurigo nodularis clinical trials currently recruiting across 177+ cities in the United States, including Philadelphia, Pennsylvania; Chicago, Illinois; New York, New York. Browse the studies above to find one at a location convenient for you.
How do I join a prurigo nodularis clinical trial?
To join a prurigo nodularis clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are prurigo nodularis clinical trials free?
Yes, participation in prurigo nodularis clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of prurigo nodularis treatments are being studied?
Current prurigo nodularis clinical trials are testing a range of approaches across NA (34 studies), PHASE2 (22 studies), PHASE3 (12 studies), PHASE1 (9 studies), PHASE4 (9 studies). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 70 research organizations.
Is it safe to participate in prurigo nodularis clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated September 2, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated September 2, 2026 · Data from ClinicalTrials.gov